We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Alexander van Akkooi

Alexander C. J. van Akkooi MD, PhD

Melanoma and Soft Tissue Sarcoma Surgeon, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Dr. Alexander van Akkooi is a board-certified surgical oncologist specializing in melanoma and sarcoma and practicing at the Netherlands Cancer Institute – Antoni van Leeuwenhoek (NCI-AVL) in Amsterdam. Dr van Akkooi is the current chairman of the EORTC (European Organization for Research and Treatment of Cancer) Melanoma Group. He is the head of the NCI-AVL Skin Cancer and Melanoma Unit. Dr van Akkooi has published over 150 peer-reviewed papers in high-impact journals, including NEJM, Lancet, Lancet Oncology, Cell, Nature Medicine, among others, and has presented at numerous international meetings. He is a member of the European Society for Medical Oncology, Society for Melanoma Research, and American Society of Clinical Oncology.

Dr. van Akkooi was awarded his medical degree from Erasmus University in Rotterdam. He was a resident in general surgery at Maasstad Ziekenhuis in Rotterdam, and underwent residency training in surgical oncology at NCI-AVL and Erasmus MC Cancer Institute. His PhD was awarded cum laude from Erasmus University.

Disclosures

Dr. van Akkooi is on the Advisory Board of & has received Consultancy Honoraria from Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Sanofi, 4SC. He also reports Research Grants from Amgen, Novartis, Merck-Pfizer which were all paid to NCI-AVL.

Recent Contributions to PracticeUpdate:

  1. Early Discontinuation of PD-1 Blockade for Advanced Melanoma After a Complete or Partial Response
  2. AACR 2021: Addition of Ipilimumab to Adjuvant Nivolumab Did Not Improve Outcomes in Late-Stage Melanoma
  3. TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma
  4. Tebentafusp Induces Anti-Tumor Immune Responses in Patients With Metastatic Melanoma
  5. Combining Nivolumab and Ipilimumab With Infliximab or Certolizumab in Patients With Advanced Melanoma
  6. 2020 Top Stories in Advanced Melanoma: The IMMUNED Trial
  7. Optimizing the Approach to Adjuvant Therapy for Resected Melanoma
  8. Immune Checkpoint Inhibition for Advanced Skin Cancer in Patients With Concomitant Hematological Malignancy
  9. Combined PD-1, BRAF, and MEK Inhibition in Advanced BRAF-Mutant Melanoma
  10. Detecting Recurrence Early in Resected Stage III Melanoma

Most Read This Week

Recently Updated